source
- BMS's Cobenfy faces market hurdles as side effects limit uptake, MapLight eyes opportunityThe FDA approved Bristol Myers Squibb's Cobenfy in 2024, marking the first novel schizophrenia treatment in 35 years and raising hopes for a new therapeutic approach. Since its launch, the drug ha…
- Regeneron Ventures leads $75 million Series A for eczema-focused antibody startup InfinimmuneInfinimmune, a Bay Area biotech developing antibody therapies for eczema, announced a $75 million Series A financing round. The round was co-led by Regeneron Ventures and Playground Global, with p…